Short Interest in Aptorum Group Limited (NASDAQ:APM) Declines By 81.4%

Aptorum Group Limited (NASDAQ:APM) saw a large decrease in short interest in May. As of May 29th, there was short interest totaling 2,482 shares, a decrease of 81.4% from the May 14th total of 13,376 shares. Based on an average daily volume of 65,802 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Aptorum Group Price Performance

NASDAQ APM traded down $0.07 during mid-day trading on Friday, reaching $0.82. The stock had a trading volume of 116,413 shares, compared to its average volume of 105,494. Aptorum Group has a 1 year low of $0.65 and a 1 year high of $4.47. The company has a fifty day moving average price of $0.90 and a 200 day moving average price of $0.97.

Aptorum Group Company Profile

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.